Ziping Wei
Co-founder & Chief Executive Officer Bliss Bio
Dr Wei holds a Ph.D. in Chemistry from Rutgers University and a B.S. from the University of Science and Technology of China. With over 30 years in biopharmaceutical development, they have contributed to more than 40 biologics and vaccine programs, including nine approved products. Their experience spans CMC roles at Novavax, MedImmune-AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson. Dr. [Name] has also authored over 80 scientific publications and contributed to monoclonal antibody guidelines for the U.S. Pharmacopoeia.
Seminars
Friday 27th February 2026
Competing in a Crowded ADC Landscape: What Does True Clinical Differentiation Look Like in Today’s ADC Market?
1:30 pm
- How can we improve toxicity profiles and delivery better than Enhertu?
- What and how are leaders achieving efficacy beyond a monospecific with a BsAb and BsADCs
- Leveraging synergy between biology of targets and binding events to improve ADC performance
